A genetic modifier suggests that endurance exercise exacerbates Huntington's disease. by Corrochano, Silvia et al.
O R I G I N A L A R T I C L E
A genetic modifier suggests that endurance exercise
exacerbates Huntington’s disease
Silvia Corrochano1,*, Gonzalo Blanco2, Debbie Williams1, Jessica Wettstein3,†,
Michelle Simon1, Saumya Kumar1, Lee Moir1, Thomas Agnew1,
Michelle Stewart1, Allison Landman1, Vassilios N. Kotiadis4,
Michael R. Duchen4, Henning Wackerhage3,5, David C. Rubinsztein6,7,
Steve D.M. Brown1 and Abraham Acevedo-Arozena1,8,*
1Mammalian Genetics Unit, Harwell Institute, Medical Research Council, Oxfordshire, UK, 2Department of
Biology, University of York, York, UK, 3Institute of Medical Sciences, University of Aberdeen, Scotland, UK,
4Department of Cell and Developmental Biology, University College London (UCL), London, UK, 5Department of
Sport and Health Sciences, Technical University of Munich (TUM), Exercise Biology, Munich, Germany,
6Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, UK ,
7UK Dementia Research Institute, University of Cambridge, Cambridge, UK and 8Unidad de Investigacio´n,
Hospital Universitario de Canarias, Fundacio´n Canaria de Investigacio´n Sanitaria e Instituto de Tecnologı´as
Biome´dicas, La Laguna, Spain
*To whom correspondence should be addressed at: Mammalian Genetics Unit, Harwell Institute, Medical Research Council, Harwell, OX11 0RD, Oxfordshire,
UK. Tel: þ44 (0)1235 841484; Email: s.corrochano@har.mrc.ac.uk (S.C.); Hospital Universitario de Canarias, Unidad de Investigacio´n, Carretera La Cuesta-Taco
S/N, San Cristo´bal de La Laguna, 38320 Tenerife, Canary Islands, Spain. Tel: þ34 922678108; Fax: þ34 922647112; Email: aacevedo@ull.edu.es (A.A.-A.)
Abstract
Polyglutamine expansions in the huntingtin gene cause Huntington’s disease (HD). Huntingtin is ubiquitously expressed,
leading to pathological alterations also in peripheral organs. Variations in the length of the polyglutamine tract explain up to
70% of the age-at-onset variance, with the rest of the variance attributed to genetic and environmental modifiers. To identify
novel disease modifiers, we performed an unbiased mutagenesis screen on an HD mouse model, identifying a mutation in
the skeletal muscle voltage-gated sodium channel (Scn4a, termed ‘draggen’ mutation) as a novel disease enhancer. Double
mutant mice (HD; Scn4aDgn/þ) had decreased survival, weight loss and muscle atrophy. Expression patterns show that the
main tissue affected is skeletal muscle. Intriguingly, muscles from HD; Scn4aDgn/þ mice showed adaptive changes similar to
those found in endurance exercise, including AMPK activation, fibre type switching and upregulation of mitochondrial bio-
genesis. Therefore, we evaluated the effects of endurance training on HD mice. Crucially, this training regime also led to detri-
mental effects on HD mice. Overall, these results reveal a novel role for skeletal muscle in modulating systemic HD pathogen-
esis, suggesting that some forms of physical exercise could be deleterious in neurodegeneration.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by pathogenic poly-glutamine expan-
sions in the huntingtin gene (HTT) (1). Overlapping pathological
mechanisms operate in HD pathogenesis, such as altered calcium
metabolism, transcriptional impairment, altered autophagy or
mitochondrial dysfunction, amongst others. Huntingtin is ubiqui-
tously expressed (2). Consequently, although primarily a neuro-
degenerative disorder, HD also causes pathological changes in
many peripheral tissues and organs including skeletal muscle (3,
4). Metabolic abnormalities in HD patients and mouse models are
well established, particularly a hypermetabolic state accompa-
nied by weight loss despite normal food intake, although their
causes are not entirely clear (5,6).
Together with the brain, skeletal muscle is the main con-
sumer of glucose, especially during exercise. Thus, changes in
skeletal muscle homeostasis, including those induced by physi-
cal exercise or by pathological abnormalities, can in turn affect
whole body metabolism, ultimately affecting the brain. In this
sense, physical exercise has been tested as a possible treatment
for HD (7). A recent clinical trial showed that moderate exercise
was not detrimental to motor functions in HD patients (8).
Studies in different HD mouse models have shown potential
beneficial effects of moderate exercise, especially observed in
hippocampal neurogenesis (9,10). However, there are also sev-
eral reports evidencing detrimental effects of exercise regimes
in HD mice, as well as inconclusive studies in HD patients (11).
To date, many HD modifier genes have been described (12),
offering potential novel therapeutic targets for further study.
Here, we conducted a screen to search for novel HD modifier
genes using the mouse as a complex model system. We identi-
fied the skeletal muscle voltage-gated sodium channel (Scn4a)
as a novel modifier gene exacerbating the overall HD disease
phenotype. The interaction of Scn4a and HD mutations leads to
higher energy demands that trigger adaptation changes in skel-
etal muscles. These adaptations are also observed after endur-
ance training regimes, allowing us to show that physical
exercise regimes leading to higher energy demands are detri-
mental in HD mice.
Results
A genetic screen in mice identifies the skeletal muscle
sodium-gated voltage channel (Nav1.4, Scn4a) as a
Huntington’s disease modifier gene
We conducted an unbiased forward dominant genetic screen in
mice that enables the identification of novel genes involved in
the systemic alterations that occur through disease progression
at the whole organismal level. Briefly, BALB/cAnN males were
mutagenized with N-ethyl-N-nitrosourea (ENU), causing
germline-transmitted random point mutations that were
crossed to congenic C57BL/6J HD transgenic females (N171–82Q)
generating mutant F1 HD mice that were then subjected to phe-
notypic screening (Supplementary Material, Fig. S1A). After
identifying individual HD phenodeviants through behavioural
phenotyping, we backcrossed them onto C57BL/6J to assess
their progeny for inheritance of the selected modifier effects.
From the modifier screen, we assessed around 350 HD F1 mice,
of which 7% were selected as potential individual phenode-
viants. Of the lines subjected to inheritance testing, 4 showed
confirmed inheritance. Here we focus on one of the enhancer
lines, that we called draggen, carrying a mutation in the Scn4a
gene. Interestingly, as well as enhancing the overall HD pheno-
type, the mutation caused a new trait, intermittent paralytic at-
tacks, appearing also independently of the HD transgene. In
previous work, we segregated the draggen mutation from the
HD transgene, cloned it and characterized it as a model of
SCN4A channelopathies, leading to non-dystrophic myotonia
and intermittent attacks of hind-limb immobility followed by
total recovery (13). Here we focus on the effects of Scn4a muta-
tions as HD modifiers. In HD; Scn4aDgn/þ mice, the draggen mu-
tation exacerbated the overall HD phenotype, including
accelerating the age at onset of tremors in HD males as well as
dramatically reducing survival (defined as the age at which a set
of humane endpoints are reached) (Fig. 1A and B). Sexual dimor-
phism was observed in the HD modifier effect (Supplementary
Material, Fig. S1B). Due to the incomplete penetrance in females,
we focused on males for the rest of the study. To confirm that
Scn4a mutations can indeed modify the HD phenotype, we
crossed HD transgenic mice to an independently generated
Scn4a allele (Scn4aM1592V/þ) (14). HD mice carrying the Scn4a
M1592V mutation (HD; Scn4aM1592V/þ) enhanced HD even more
severely than the draggen mutation in both males and females
(Fig. 1C and Supplementary Material, Fig. S1C). Thus, Scn4a mu-
tations modify the overall HD phenotype in mice.
As expected, Scn4a mRNA levels measured via qPCR are pri-
marily expressed in skeletal muscle with marginal expression
in the heart and practically no expression in brain; this expres-
sion pattern is not altered by the draggen mutation
(Supplementary Material, Fig. S2A). We confirmed these results
by analysing B-galactosidase staining on a Scn4a null allele car-
rying a LacZ reporter (Supplementary Material, Fig. S2B).
Moreover, the mutant huntingtin transgene in N171–82Q mice
is expressed in skeletal muscle at about half of the expression
levels seen in brain (Supplementary Material, Fig. S2C). Thus,
skeletal muscle is the only tissue showing high levels of expres-
sion for both genes. Due to the unique expression pattern of
Scn4a, the study of its HD modifier effect allowed us to identify
changes specifically in skeletal muscle that could be detrimen-
tal for systemic HD pathogenesis. To evaluate if the genetic in-
teraction between the mutated forms of huntingtin and Scn4a
could enhance HD pathology in the brain, we measured soluble
mutant huntingtin and huntingtin intranuclear inclusions at
piriform cortex and cerebellum (Supplementary Material, Fig.
S2D and E), finding no differences between genotypes. In con-
trast, soluble mutant huntingtin levels were increased in HD;
Scn4aDgn/þ skeletal muscles when compared to HD; Scn4aþ/þ lit-
termates (Fig. 1D).
One of the most important features observed in HD patients
and mouse models is severe weight loss, which is partially ex-
plained by a hypermetabolic state (15) and progressive skeletal
muscle atrophy. We evaluated whether accelerated muscle
wasting and cachexia could be a possible cause of the early
death observed in HD; Scn4aDgn/þ mice. We observed that HD;
Scn4aDgn/þmale mice suffered from further progressive weight
loss when compared to draggen or HD males alone (Fig. 1E).
This is reflected in a tendency towards increasing in vivo whole
body energy expenditure of HD; Scn4aDgn/þ when compared to
HD; Scn4aþ/þ littermates at 8 weeks of age, with no major
changes in food intake at this age (Supplementary Material, Fig.
S3A). The weight differences between HD; Scn4aþ/þ and HD;
Scn4aDgn/þ males were mainly explained by a reduction in fat
mass progressively until disease end-stage (Fig. 1F).
Interestingly, at disease end-stage for double mutants (12 weeks
of age), there is further loss of lean mass. At this end-stage, in
double mutant mice, energy expenditure is still high compared
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to control wild-type mice (although similar to control HD;
Scn4aþ/þ mice), also showing a tendency towards a lower food
consumption (Supplementary Material, Fig. S3B). This decrease
in fat mass in HD; Scn4aDgn/þ is consistent with changes in adi-
ponectin levels and reduction of free fatty acid levels in plasma
of HD; Scn4aDgn/þ male mice (Fig. 1G).
All these data together suggest that the genetic interaction
between Scn4a and HD mutations further increases the already
elevated energy turnover of HD mice, potentially depleting the
body of different energy sources that may accelerate the disease
in double mutant mice.
Scn4amutations lead to mitochondrial enlargement and
metabolic adaptations in HD skeletal muscle
We have previously observed that draggen mice when not in
the context of the HD transgene (WT; Scn4aDgn/þ) have increased
muscle activity (myotonia and intermittent paralytic attacks)
which activated adaptive non-dystrophic changes, switching
skeletal muscle fibres towards more oxidative types (13). These
changes are physiological in a plastic tissue like skeletal muscle,
but could be detrimental in a disease context. Thus, we first ex-
amined if these adaptive responses were also present in HD;
Scn4aDgn/þ mice, as they could be contributing towards the ac-
celerated cachexic state in double mutants. First, we focussed
on AMPK activation, the master energy sensor that is activated
via phosphorylation when there is a deficit in energy supply.
Interestingly, AMPK is activated to similar levels in skeletal
muscle of HD; Scn4aDgn/þ and WT; Scn4aDgn/þmice, an activation
likely driven by the draggen mutation alone (Fig. 2A). Despite
similar AMPK activation levels in skeletal muscle between WT
controls (WT; Scn4aþ/þ) and HD transgenic mice (HD; Scn4aþ/þ),
the levels of the AMPK-controlled glucose transporter GLUT-4
were downregulated in skeletal muscle in HD mice when com-
pared to non-transgenic controls (Fig. 2B), providing a potential
explanation for the higher free-fed glucose levels in serum of
HD mice (Fig. 2C). Interestingly, the increase in AMPK activation
in HD; Scn4aDgn/þ mice leads to a normalization of GLUT-4 in
skeletal muscle to levels similar to WT mice (WT; Scn4aþ/þ), but
still higher than HD controls (HD; Scn4aþ/þ). As a consequence,
glucose levels are significantly reduced in HD; Scn4aDgn/þ when
compared to any other genotype (Fig. 2C). We validated these
results by a glucose tolerance test (Supplementary Material, Fig.
S3C), showing that HD; Scn4aDgn/þ are more efficient in their glu-
cose uptake than HD controls. Overall, these results provide a
potential mechanistic explanation for the reduced glucose lev-
els observed in HD; Scn4aDgn/þ mice.
Another adaptive consequence of the activation of AMPK in
response to energy deprivation is the triggering of a mitochon-
drial biogenesis programme, leading to a shift of muscle fibres
towards more oxidative types (16). Indeed, we found an almost
complete muscle fibre switching towards more oxidative types
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Figure 1. Scn4a mutations exacerbate HD leading to further metabolic alterations. (A) Cumulative tremor onset events from 7 weeks of age (HD; Scn4aþ/þ (n¼20) average
onset: 10.1 weeks; HD; Scn4aDgn/þ (n¼31) average onset: 8.4 weeks. P<0.001). (B) Draggen mutation decrease survival on HD males (HD; Scn4aþ/þ (n¼28) average sur-
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(n¼12) average survival: 15.8 weeks; HD; Scn4aM1592V/þ (n¼14) average survival: 7.7 weeks. P< 0.001). (D) Representative immunoblot and analysis of levels of soluble
mutant huntingtin from TA muscle corrected by GAPDH (n¼5, P¼0.0018). (E) Body weights from 5 weeks of age until disease end-point. At least 13 male mice per geno-
type and time-point, (P<0.05 from 5 weeks onwards comparing HD; Scn4aDgn/þ to any other group). (F) Whole body fat and lean mass in male mice at 8 (n¼ 5 nonHD
and n¼8 HD groups) and 12 weeks of age (n¼5 nonHD groups and n¼10 HD groups). (G) Free-fed circulating levels of adiponectin and free-fatty acids in plasma of
male mice at 12 weeks of age (n¼5 nonHD and n¼8 HD groups). WT¼WT; Scn4aþ/þ, Dgn¼WT; Scn4aDgn/þ, HD; WT¼HD; Scn4aþ/þ and HD; Dgn¼HD; Scn4aDgn/þ.
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within the tibialis anterior (TA) muscle of draggen mice (in WT;
Scn4aDgn/þ mice and to a greater extent in HD; Scn4aDgn/þ) (Fig.
2D and Supplementary Material, Fig. S4A and B). At the electron
microscopy level, enlarged mitochondria appeared in skeletal
muscle from HD; Scn4aDgn/þ mice at 12 weeks of age (Fig. 2E).
This increased mitochondrial mass in HD; Scn4aDgn/þ mice was
confirmed by mitochondrial DNA analysis and by increased lev-
els of mitochondrial components of the OXPHOS respiratory
chain subunits (Supplementary Material, Fig. S4C and D). It has
been previously shown that mutant huntingtin interferes and
disrupts the normal functioning of mitochondria at several lev-
els (17–19). To determine whether those enlarged mitochondria
were functional, we measured respiration from the dissociated
muscle fibres from mice ex vivo. There was an increase in the
overall Oxygen Consumption Rate (OCR), including a significant
increase in the maximal uncoupled respiration rate of HD;
Scn4aDgn/þ compared to HD; Scn4aþ/þ muscle bundles (Fig. 2F),
which as a consequence is associated with an increased produc-
tion of reactive oxygen species (ROS).
Overall, all these observations suggest that HD skeletal mus-
cle is still capable of adapting to higher energy demands (such
as the one posed by the increased activity due to Scn4a
mutations), activating AMPK, enhancing mitochondrial function
and increasing different fuel consumptions. Despite these adap-
tations, there is a dramatic acceleration of disease in HD;
Scn4aDgn/þ mice, suggesting a detrimental effect for HD
pathogenesis.
Endurance exercise training is detrimental for
HD in mice
The effect of Scn4a mutations in skeletal muscle partially re-
sembles the adaptations induced by endurance training exer-
cise, leading to non-dystrophic changes mediated by
constitutive AMPK activation (20,21). It is very unlikely that a
Huntington’s patient would also carry a SCN4A mutation.
However, HD patients could carry other genetic variations af-
fecting their energy balance and/or skeletal muscle activity, as
well as variations modulating the response to environmental
stimuli such as physical exercise. In this context, the effects of
physical exercise in HD pathogenesis are still controversial, but
are currently considered as a potential intervention that could
be beneficial for HD (7) and other neurodegenerative disorders.
However, according to our results, adaptations induced by
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increasing energy demands in skeletal muscle, including endur-
ance exercise, might be detrimental for HD pathogenesis. Thus,
to test this hypothesis, we established an endurance training
routine for HD and WT littermate male mice, starting at 7 weeks
of age and lasting for 6 weeks. First, we showed that the regime
led to AMPK activation in skeletal muscle of HD mice (Fig. 3A).
We studied body composition before and after the endurance
exercise regime, showing that exercised HD mice lose lean
mass faster than sedentary HD controls by 12 weeks of age
(Fig. 3B). Crucially, HD mice undergoing endurance training
reached the humane endpoints significantly earlier than their
sedentary HD littermates (Fig. 3C). Remarkably, and concor-
dantly with the findings in HD; Scn4aDgn/þ muscles, enlarged mi-
tochondria were also present in exercised HD mice, but not in
their sedentary littermates at 13 weeks of age (Fig. 3D). Thus, at
least in the mouse, endurance training leading to constitutive
activation of AMPK in skeletal muscle is detrimental for HD
pathogenesis.
Discussion
Through an unbiased genetic screen in mice we have identified
Scn4a as a novel HD modifier. As Scn4a is primarily expressed in
skeletal muscle, analysis of the modifier effect highlighted a
novel critical role of the periphery in modulating systemic HD
pathogenesis. The phenotypic modification occurs through a
mechanism mediated by AMPK activation inducing skeletal mus-
cle adaptations leading to high-energy demands. We propose
that this energetic imbalance produced by skeletal muscle adap-
tations ultimately exacerbates systemic HD progression. Thus, to
test this hypothesis independently of Scn4a mutations, we sub-
jected HD mice to an endurance training regime that phenocop-
ies the adaptive changes present in skeletal muscle of HD;
Scn4aDgn/þ mice. As we anticipated, endurance exercise was detri-
mental for HD mice. Thus, the critical linking point between the
two sets of experiments is that they both highlight a critical role
for the periphery in modulating systemic HD pathogenesis.
Overall, using two independent approaches in mice, we showed
that skeletal muscle adaptations mediated by constitutive AMPK
activation are detrimental for systemic HD pathogenesis.
Mitochondrial impairment and energy balance dysregula-
tion have been previously associated with HD pathogenesis (15,
22,23). Thus, interventions aimed at increasing energy produc-
tion or mitochondrial biogenesis either by genetic means, phys-
ical exercise or drugs, have been proposed and tested as
potential treatments for HD and other neurodegenerative disor-
ders. Moreover, a recent clinical trial showed that moderate ex-
ercise stabilized motor functions in HD patients, although
bigger study sizes are needed to assess other effects (8).
However, there are several reports evidencing detrimental ef-
fects of exercise regimes in HD mice (24) as well as inconclusive
studies in HD patients (11). Furthermore, activation of AMPK by
injection of the AMPK-activating drug AICAR increased neuro-
nal death and decreased lifespan in HD mice (25). Our data here
provides a potential explanation for the inconsistencies on the
effects of physical exercise in HD pathogenesis, as some re-
gimes but not others may lead to adaptive changes in skeletal
muscle. In light of our data, the potential benefits of augment-
ing mitochondrial function in HD may be enhanced when ac-
companied by increasing fuel supply.
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Overall, our findings suggest caution to interventions aimed
at HD patients that may lead to higher energy demands, includ-
ing stringent physical exercise or drugs aimed at increasing mi-
tochondrial function.
Materials and Methods
Mice
Mice were kept under a controlled 12-h light cycle and had free
access to water and were fed ad libitum on a commercial diet
(SDS). Draggen mice were identified through a dominant modi-
fier ENU screen (26) injecting BALB/c male mice with ENU and
crossing them with (N171–82Q) HD hemizygous carrier females
on a C57BL/6J background. All G1 mice produced were geno-
typed for the HD transgene and were subject to a behavioural
screening pipeline including: general dysmorphology and
SHIRPA analysis, weight and grip-strength measurements.
Identified individual G1 pheno-deviant mice that showed novel
phenotypes or modulate the HD disease onset of progression of
the parental N171–82Q HD line on a C57BL/6J-BALB/c hybrid
background were selected for further analysis and backcrossed
onto C57BL/6J to assess inheritance. After inheritance was es-
tablished, a positional cloning approach was followed using a
panel of single nucleotide polymorphisms (SNPs) polymorphic
between the two parental strains.
The draggen mutation was first identified in the context of
the HD transgene through the ENU modifier screen. After back-
crossing to C57BL/6J, the draggen mutation was segregated from
the HD transgene. The cloning of the draggen mutation and the
characterization of the draggen mice when not in the context of
the HD mutation has already been published, using the charac-
teristic intermittent attacks of hind-limb immobility as the ini-
tial phenotypic selected trait. The draggen official allele name
is: Scn4am1Aaa. Mice homozygous for the draggen mutation are
not viable, therefore all the work performed here is on heterozy-
gous draggen carriers.
Draggen mice used here are at least N3 (three generations of
backcross onto C57BL/6J); the colony is currently backcrossed
for >10 generations onto C57BL/6J (>N10). All mice produced for
this study were obtained by intercrossing both mutations in
heterozygosis, producing all four possible genotypes from the
same cross (WT; Scn4aþ/þ, WT; Scn4aDgn/þ, HD; Scn4aþ/þ and HD;
Scn4aDgn/þ), allowing to use littermate controls. Experiments
were performed blind to genotype and lifespan was defined by
mice reaching one of the following humane end-points: loss of
20% of maximum body weight, the presence of hunched posture
and piloerection or the appearance of hind-limb paralytic at-
tacks lasting longer than 1 min with no full recovery.
Scn4aM1592V/þ (FVB.129S4(B6)-Scn4atm1.1Ljh/J) mice were pur-
chased from Jackson laboratories (USA) on a congenic FVB back-
ground and generated the four desired genotypes by crossing
WT; Scn4aM1592V/þ to HD; Scn4aþ/þ mice. Scn4aM1592V/þ mice were
maintained in a hybrid C57BL/6J-FVB background. All genotyp-
ing was performed by pyrosequencing or light scanner (For pri-
mer list used, see Supplementary Material, Table S1).
Scn4a deficient mice (Scn4atm2b(KOMP)Wtsi) were produced at
MRC Harwell through the IMPC programme and are distributed
through the European Mouse Mutant Archive (www.infrafront
ier.eu). Cre expression deleted the critical exon, producing a
lacZ tagged null allele.
Phenotyping tests
The number of animals was chosen based on previous studies.
For in vivo behavioural tests we required a minimum of seven
mice per sex and genotype. Modified SHIRPA methods were per-
formed as described previously (27,28). Tremors were qualita-
tively assessed by observation in a viewing jar and recorded as
having no tremors (0), mild tremors (1), moderate tremors (2) or
severe tremors (3). Mice were subject to modified SHIRPA analy-
sis from 7 weeks of age until they reached their humane end-
point. Paralytic attacks were evaluated weekly as previously
described (13).
Metabolic rate was measured at 8 and 12 weeks of age, with
measurements performed for 22 h during the light and dark pe-
riod, using indirect calorimetry TSE systems to determine
Energy Expenditure (E.E.). Fat and lean mass in the body were
determined by EchoMRI (EchoMRI-100TM) scan system. For in-
traperitoneal glucose tolerance test (IPGTT), mice were fasted
overnight (16 h) to establish a baseline glucose level ‘T0’ (time
zero). A blood sample was collected from the tail vein after ad-
ministration of local anesthetic. Mice were then injected intra-
peritoneally with 2 g of glucose per kg body weight (20% glucose
in 0.9% NaCl). Blood samples were taken at 15, 30, 60 and 120
min after injection and glucose was measured using Alphatrak2
glucose analyser (Abbott Laboratories, USA).
Endurance exercise challenge
Wild type and HD N171–82Q male mice littermates on a con-
genic C57BL/6J background had 30 min of forced exercise in the
rotarod at constant speed (15 rpm), 5 days a week, plus a run-
ning wheel in their home cages, allowing for additional volun-
tary exercise. The routine started from pre-symptomatic
(around 7 weeks of age) until they reached the humane end
points in the case of HD mice (for survival analysis), or until 12
weeks of age for nonHD mice and for HD mice used for molecu-
lar analysis. Wild type and HD littermates were used for the
sedentary group controls. Fat and lean mass in the body were
determined by EchoMRI before (at the beginning of the experi-
ment) and after 5 weeks of training.
Blood parameters
Terminal blood samples were collected from mice aged 12 weeks
(n¼ 5–7 per group). Mice were fasted 4 h prior to blood collection.
Blood samples were collected under terminal isofluorane inhala-
tion anaesthesia by retro-orbital puncture into paediatric lithium
heparin coated tubes. Lithium heparin samples were kept on wet
ice until being centrifuged for 10 min at 8000g at 4C. The result-
ing plasma was analysed on board a Beckman Coulter AU680
clinical chemistry analyser using reagents and settings recom-
mended by the manufacturer. Plasma mouse adiponectin was
measured using an ELISA kit from Life Technology.
Respiration analysis in muscles ex vivo
Respiration measurements were made from muscle bundles ex
vivo using a high-resolution respirometry system Oxygraph-2k
(Oroboros Instruments, Bioblast) which allows for the analysis
of mitochondrial respiratory chain activity from mouse muscle
fibers. We compared oxygen consumption rates (OCR) of exten-
sor digitorum longus (EDL) muscle from male mice aged 12
weeks (HD; Scn4aþ/þ n¼ 6, and HD; Scn4aDgn/þ n¼ 5). Briefly, dis-
sected EDL muscles were placed in ice-cold BIOPS solution (10
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mM Ca-EGTA buffer, 0.1 mM free calcium, 20 mM imidazole, 20 mM
taurine, 50 mM K-MES, 0.5 mM DTT, 6.56 mM MgCl2, 5.77 mM ATP,
15 mM phosphocreatine, pH 7.1) and were separated lengthways
to obtain bundles of fibres. Three bundles per EDL were permea-
bilized with saponin for 30 min in ice-cold BIOPS, prior to wash-
ing and transferring to the mitochondrial medium for OCR
measurements in the Oroboros chambers according to the man-
ufacturer’s protocol. A specially designed substrate/inhibitor ti-
tration approach allowed the step-by-step analysis of the
activity of the respiratory chain (RC) as a whole as well as the
relative contribution to total activity of RC complexes I and II,
the two entry points for electrons. Additions of substrates and
inhibitors were in the following order and final concentration:
Malate 2 mM, Glutamate 10 mM, ADP 2.5 mM, Cytochrome c 10
mM, Succinate 10 mM, titrations of 0.25 mM with the protonophore
uncoupler Carbonyl cyanide 4-(trifluoromethoxy)phenylhydra-
zone (FCCP) until maximal uncoupled respiration was reached,
Rotenone 0.5 mM, and finally Antimycin A 2.5 mM. State 2 respira-
tion was obtained following additions of Malate and Glutamate,
State 3 after ADP, Maximal uncoupled after FCCP. The relative
proportion of total respiratory chain activity dependant on ei-
ther of the two entry points of the RC (i.e. Complex I and II) were
measured as the Rotenone sensitive component of Maximal
Uncoupled respiration for complex I and the remaining activity
as that for Complex II. After the experiment, muscle bundles
were recovered, homogenized and total protein concentration
was measured in order to correct the OCRs by the total amount
of protein per chamber. For the acquisition and analysis of data
the manufacturers DatLab software was used (Oroboros
Instruments, Austria).
Histology
Tibialis anterior (TA) from male mice for the four genotypes (n¼ 3
per group) were dissected at 12 week of age, weighed and snap
frozen and 10 mm sections were cut in a cryostat. TA sections
were stained for NADH-tetrazolium reductase and ATPasa.
To detect mutant human huntingtin intranuclear inclusions
in the brain, we conducted the same protocol as previously de-
scribed (29). Mice were transcardially perfused with 4% parafor-
maldehyde (PFA), brain removed and placed in PFA for another
4–6 h. After 30% sucrose protection, brains were crypreserved at
80 until used. Free-floating cryosections at 30 mm were immu-
nostained against mutant huntingtin using mouse anti- human
polyQ (MAB5374 Millipore, 1:500) overnight. The seconday anti-
body was Alexa 488 (Life Technology) and nuclear DAPI counter-
staining (Prolong, Life technology). Confocal images were taking
using Zeiss LSM 700 microscope at 60 amplification of the
granular layers in the cerebellum. Final images stack projec-
tions (typically the sum of 8 images per projection) were used to
count the total of inclusions per field. A minimum of three fields
per slice, over 3 or 4 slices were used to account for the total
number of inclusions per mouse. Volocity software 5.4.1 (Perkin
Elmer, USA) was used to analyse the total count and classified
by the size of the inclusions per image. The given data is a rela-
tive proportion of each size group to the total, falling into four
categories, from the smallest aggregates (0–2 mm2) to the biggest
inclusions found (>6 mm2).
Transmission electron microscopy
Mice were perfused with a mix of 2% glutaraldehyde and 2%
paraformaldehyde in PBS. TA muscles were dissected and
placed in 1% OsO4 on ice for 1 h followed by two 5 min washes
with Phosphate buffer (100 mM NaH2PO4/Na2HPO4.2H20). The
samples were dehydrated through an ethanol series (30%, 50%,
70%, 95% and absolute) and transferred to a 1: 1 mixture of
Epon/Araldite and acetone and incubated overnight with mix-
ing. The solution was then replaced with a 1: 1 mixture of 100%
Epon/Araldite and incubated for 6 h, followed by another re-
placement with fresh Epon/Araldite and overnight incubation
with mixing. Samples were transferred to fresh Epon/Araldite in
embedding molds and oriented as required. Polymerization of
the Epon/Araldite mold was completed at 65C for 48 h. 70 nm
sections were produced and stained with saturated uranyl ace-
tate and Reynolds’ lead citrate. All images were obtained with a
Tecnai 12 BioTWIN made by FEI, Eindhoven. Quantification of
the TEM images was done by Image J software.
Immuno-blot analysis
Snap frozen TA muscles and forebrain from male 12 week-old
male mice were homogenized in RIPA buffer (150 mM NaCl, 1%
NP40, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris pH 7.5) with
phosphatase and protease inhibitor cocktails (Roche), using lys-
ing matrix tubes D (MP Biomedicals, Germany) and a Fast-Prep-
24 homogenizer at 4C. Homogenates were centrifuged at
12 000g 4C for 20 min. 40 lg of soluble fractions were resolved
by SDS–PAGE (NUPAGE system, Invitrogen) and transferred to
low fluorescent PVDF (PVDF-LF) membranes (Millipore) for
western-blot analysis. The following primary antibodies were
used: rabbit monoclonal anti-actin (A2066, Sigma, 1:3000);
mouse anti-a tubulin (ab7291, abcam, 1:3000), mouse anti-
GAPDH (ab8245, abcam, 1:5000); mouse anti-soluble human
polyQ (MAB1537–1C2, Millipore, 1:800), rabbit anti-p-AMPKa
(Thr-172, 2535–40H9) and mouse anti-total AMPKa (2793, both
Cell Signalling, 1:1000); rabbit anti-GLUT-4 (CBL243, Millipore).
Total protein loading and transfer was also quantified using
REVERT kit (Li-Cor Biosciences). Protein was visualized using
anti-mouse or anti-rabbit secondary antibodies IRDyeVR (Li-Cor
Biosciences) at 1: 10 000 dilutions and quantified using the infra-
red Odyssey imaging system (Li-Cor Biosciences).
Mitochondria DNA analysis
Extensor Digitorum Longus fast muscles were used to quantify
the amount of mitochondria DNA in all experimental groups by
quantitative PCR (males, n¼ 7 per group). DNA extraction was
performed using DNA-blood and tissues kit (Qiagen) following
manufacturer’s instructions. The sequences of the primer used
are detailed in Supplementary Material, Table S1.
Gene expression analysis
RNA extraction was performed using RNeasy kit (Qiagen) from
whole brain and Quadriceps. The quantity of the RNA was
checked using a nanodrop and the quality was assessed using
Bioanalyser. RINs of over 7.5 were always observed. cDNA syn-
thesis was performed using the High Capacity cDNA RT kit
(ThermoFisher Scientific) starting with 2 mg of RNA. cDNA was
at a final concentration of either 20 or 50 ng per well depending
upon the gene being studied. All the reactions were run in tripli-
cate. The real-time experiments were performed on a 7900 fast
machine (ThermoFisher Scientific). For the probe based experi-
ments, TaqMan Fast Universal PCR Master was used and the re-
actions had a final volume of 20 ml, and Taqman assays
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(ThermoFisher Scientific) used as per manufactures recommen-
dations. For the sybr experiments; fast Sybr Green mastermix
from ThermoFisher Scientific was used and the reactions had a
final volume of 20 ml. Primers were at a final concentration of
360 nM. Primers were designed to span exon-exon boundaries
and are listed in Supplementary Material, Table S1. Fold
changes were calculated using the 2-ddCt method using the
7500 Software v2.0.6 and normalized using S16 or S18 endoge-
nous reference genes relative to HD; Scn4aþ/þ genotype (30).
Statistical analysis
Error bars represented SEM. P values of <0.05 were considered
significant. P values comparing two HD groups were calculated
using the two-tailed Student’s t-test (with Welch’s correction or
Mann–Whitney when appropriate) and ANOVA with Tukey
postHoc analysis. Log-Rank test was used for survival and age
at onset analysis, and ANCOVA regression model for Energy
Expenditure analysis.
Study approval
All animal studies were carried out in accordance with UK
Home Office legislation and local ethical guidelines. Mice char-
acterization followed ARRIVE guidelines.
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